Trials / Unknown
UnknownNCT03843749
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Changzheng Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial aims to evaluate the efficacy, safety of Pyrotinib in combination with trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyrotinib | Pyrotinib in Combination With Trastuzumab |
Timeline
- Start date
- 2019-07-01
- Primary completion
- 2019-07-01
- Completion
- 2022-07-01
- First posted
- 2019-02-18
- Last updated
- 2019-02-18
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03843749. Inclusion in this directory is not an endorsement.